Intervention
Sotagliflozin
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 23 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
23 shownSotagliflozin in Patients With Heart Failure Symptoms and Type 1 DiabetesNCT06435156 · 2025-01-28
RECRUITINGSotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney DiseaseNCT06217302 · 2024-10-31
RECRUITINGMultifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesNCT06082063 · 2024-07-01
RECRUITINGPrecision T1D Platform - New Therapies for Cardio-Renal ComplicationsNCT07594145 · 2026-11-01
NOT_YET_RECRUITINGRapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)NCT07547878 · 2026-04-30
NOT_YET_RECRUITINGAntithrombotic Activities of Sotagliflozin vs. EmpagliflozinNCT06618976 · 2025-02-25
COMPLETEDPrevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxiaNCT06147232 · 2025-02-01
NOT_YET_RECRUITINGCombination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 DiabetesNCT05696366 · 2024-09-09
ACTIVE_NOT_RECRUITINGSotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) PatientsNCT05562063 · 2022-10-26
COMPLETEDEffect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)NCT03521934 · 2018-06-15
TERMINATEDEfficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlNCT03386344 · 2018-02-19
TERMINATEDEffect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskNCT03315143 · 2017-12-19
TERMINATEDSafety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart FailureNCT03292653 · 2017-12-04
TERMINATEDEfficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminNCT03351478 · 2017-11-27
COMPLETEDEfficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic AgentsNCT03285594 · 2017-09-15
COMPLETEDSafety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlNCT03242252 · 2017-08-16
COMPLETEDA Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlNCT03242018 · 2017-08-16
COMPLETEDA Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AloneNCT02531035 · 2015-09-01
COMPLETEDDose-ranging Study in Patients With Type 1 Diabetes MellitusNCT02459899 · 2015-07-01
COMPLETEDEfficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyNCT02421510 · 2015-05-01
COMPLETEDEfficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1CNCT02383940 · 2015-04-01
COMPLETEDEfficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin TherapyNCT02384941 · 2015-03-01
COMPLETEDSafety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes MellitusNCT01742208 · 2013-02-01
COMPLETEDCommon conditions
Type 2 Diabetes Mellitus7Heart Failure5Type 1 Diabetes Mellitus5Type 1 Diabetes4Diabetic Nephropathies2Albuminuria1Cardiac Failure Aggravated1Cardio-renal Vascular Function and Failure1Cardiovascular Diseases1Chronic Kidney Disease1Chronic Kidney Disease Stage 31Chronic Kidney Disease Stage 41Chronic Kidney Diseases1Diabetes Mellitus Type 11Diabetes Mellitus, Type 11Diabetic Chronic Kidney Disease1Diabetic Complications Cardiovascular1Diabetic Complications Renal1Heart Failure With Preserved Ejection Fraction1High Level of Sugar (Glucose) in the Blood1Hypoxia1Kidney Failure1Kidney Failure, Chronic1Nephropathy1T1D Heart Failure1
Leading sponsors
Trial status mix
COMPLETED12
TERMINATED4
NOT_YET_RECRUITING3
RECRUITING3
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE312
PHASE28
PHASE43
PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.